Ganesh Gopalakrishna, MD
Psychiatry · Columbia, MONPI 1891995262
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (44.1%), travel and lodging and consulting fees — rather than concentrated in one kind of arrangement. Eisai Inc. accounts for 72.3% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2024 at $1,475 and has fallen 94.6% since, to $80 in 2025.
Across 21 payments — averaging $89.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eisai Inc.$1K
- Roche Molecular Systems, Inc.$300
- Roche Diagnostics Corporation$123
- F. Hoffmann-la Roche AG$80
- Kowa Pharmaceuticals America, Inc.$15
Across 64 payments — averaging $19,585 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$835K
- Eli Lilly$404K
- Novartis$14K
What the payments were for
- Consulting fees$30016%
- Travel & lodging$74540%
- Food & beverage$82544%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eisai Inc. | 17 | $1,351 |
| Roche Molecular Systems, Inc. | 1 | $300 |
| Roche Diagnostics Corporation | 1 | $123 |
| F. Hoffmann-la Roche AG | 1 | $80 |
| Kowa Pharmaceuticals America, Inc. | 1 | $15 |
How this compares
$1,870 in reported general payments places this provider in the 75th percentile of 680 psychiatry providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Rivastigmine | 45 | $6,559 |
| Memantine Hcl | 131 | $3,416 |
| Donepezil Hcl | 200 | $2,203 |
| Galantamine ErGalantamine Hbr | 11 | $1,598 |
| Escitalopram Oxalate | 144 | $1,361 |
| Quetiapine Fumarate | 54 | $990 |
| Galantamine Hbr | 23 | $984 |
| Trazodone Hcl | 45 | $346 |
| Buspirone Hcl | 16 | $229 |
| Sertraline Hcl | 15 | $158 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Columbia
- Joseph ParksColumbia$63K
- Agara ReddyColumbia$12K
- Gregory MattingleySaint Charles$4.7M
- Vadim BaramSaint Louis$1.9M
- Adam SkySaint Louis$1.1M
- Mohd MalikSaint Louis$956K
- Brian BarashKansas City$856K
- Casey ProughLees Summit$615K
- George GrossbergSaint Louis$501K
- Shahid InsafBranson$416K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.